Brain metastases lung adenocarcinoma patients with BRG1 loss have a grim prognosis, featuring unique morphological and methylation characteristics
Clinical & Experimental Metastasis · 2025
DOI: 10.1007/s10585-025-10337-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical & Experimental Metastasis, 2025. Verfasst von Junjie Yang und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Sanbo Brain Hospital, Capital Medical University, Xiangshan Yikesong 50, Haidian District, Beijing, 100093, China. Hauptthemen laut MEDLINE: Brain Neoplasms, DNA Helicases, DNA Methylation, Nuclear Proteins. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
BRG1 deficiency in patients with lung adenocarcinoma that has metastasized to the brain, termed BRG1-deficient brain metastasis lung adenocarcinoma, is an uncommon event. Prior to this study, these patients had not undergone extensive molecular and (epi)genetic analysis. We report a comprehensive clinical, histopathologic, and molecular assessment of 9 BRG1-deficient brain metastasis lung adenocarcinoma cohort (BRG1-deficient BM cohort) in comparison with a 16 BRG1-retained brain metastasis lung adenocarcinoma cohort (BRG1-retained BM cohort). Patients with BRG1-deficient BM exhibited a significantly increased risk of mortality. Molecular analysis revealed a high prevalence of mutations in SMARCA4 and TP53 genes within this group. DNA methylation molecular diagnostics showed a high rate of genomic instability and a markedly lower DNA methylation age in these patients. Functional enrichment analysis of differentially methylated genes suggested that hypomethylation genes were primarily associated with the negative regulation of neuron differentiation, G protein-coupled receptor signaling pathways, and cell differentiation. Conversely, hypermethylation was linked to the regulation of small GTPase mediated signal transduction, Rho protein signal transduction, DNA damage response, and apoptotic processes. This study investigated a rare subgroup of lung adenocarcinoma patients with brain metastasis characterized by BRG1 deficiency and a poor prognosis. Our study not only provides a comprehensive multi-omic data resource but also provides valuable biological insights into patients. The findings may serve as a valuable reference for the future pathological diagnosis of BRG1-deficient brain metastasis in lung adenocarcinoma patients.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology, Sanbo Brain Hospital, Capital Medical University, Xiangshan Yikesong 50, Haidian District, Beijing, 100093, China.
- Department of Neurosurgery, Capital Medical University, Beijing, 100070, China.
- Department of Pathology, Sanbo Brain Hospital, Capital Medical University, Xiangshan Yikesong 50, Haidian District, Beijing, 100093, China. xszqxl169@mail.ccmu.edu.cn.
Zitieren
APA
Yang, J., Feng, J., Duan, Z., Liu, X., Zhang, H., Zhang, M., Ma, Z., Hu, Z., Xiang, L., & Qi, X. (2025). Brain metastases lung adenocarcinoma patients with BRG1 loss have a grim prognosis, featuring unique morphological and methylation characteristics. Clinical & Experimental Metastasis. https://doi.org/10.1007/s10585-025-10337-2
Vancouver
Yang J, Feng J, Duan Z, Liu X, Zhang H, Zhang M, et al. Brain metastases lung adenocarcinoma patients with BRG1 loss have a grim prognosis, featuring unique morphological and methylation characteristics. Clinical & Experimental Metastasis. 2025. doi:10.1007/s10585-025-10337-2
BibTeX
@article{Yang2025,
author = {Yang, Junjie and Feng, Jing and Duan, Zejun and Liu, Xing and Zhang, Hongwei and Zhang, Mingshan and Ma, Zhong and Hu, Zejuan and Xiang, Lei and Qi, Xueling},
title = {Brain metastases lung adenocarcinoma patients with BRG1 loss have a grim prognosis, featuring unique morphological and methylation characteristics},
journal = {Clinical & Experimental Metastasis},
year = {2025},
doi = {10.1007/s10585-025-10337-2}
}
EUVIMED